South Florida Physician Drug Testing Fraud: The Signature Behind the Lab Bill

In the FBI’s account of the criminal case, a physician in the South Florida treatment network reviewed 100 tests in one hour, according to records examined by the investigating agent. The agent described the physician clicking to process tests without examining them. The physician pleaded guilty to conspiracy to commit health care fraud.

Clinical signoff is the part of that business a physician, treatment worker or laboratory employee may recognize from inside. Who chose the test? Who considered the result? Where did either decision enter the patient’s care?

What Makes a Test Review Clinically Meaningful?

A meaningful test review connects the result to the patient’s condition and treatment. The 2016 article How Urine Drug Testing Fraud and Abuse Is Impacting the Treatment Community, published in BNA’s Health Care Fraud Report, separates the physician’s independent decision to order a test from the later work of reviewing its result and considering what it means for care.

The article makes that distinction concrete: follow-up visits, specific analysis of results and changes in treatment, with testing becoming less frequent as a patient’s progress warrants. It contrasts ongoing care with an initial visit followed by indefinite testing. A repeating order can keep producing specimens and bills long after the original visit.

The physician’s recorded test reviews make that distinction concrete. The FBI account describes approvals moving through the system without examination of the results. For someone who handled those results, the question is what clinical work stood behind the approval.

The Physician’s Orders and Examination Bills

The Justice Department’s announcement in the physician’s criminal case describes how the medical director enabled the testing. The operator dictated its type and frequency according to payments from laboratories. The physician signed urine-testing orders and medical-necessity certificates for saliva tests, including for patients he had never seen. He knew the unnecessary tests would be billed to their insurers.

The medical director was supposed to evaluate patients and prescribe medically necessary treatment and testing. The announcement describes a different sequence: laboratory payments influenced the operator’s instructions, and the physician supplied the orders and certificates that let the testing proceed. The person signing the clinical document and the person deciding how often to test occupied different roles in the business.

That is a connection a treatment worker might recognize from scheduling and orders. An instruction to send patients for another test can reach staff before anyone has assessed whether the previous result calls for a change in care. We would connect the instruction, the physician’s order and the laboratory claim to understand who made each decision and what the clinical record says happened.

The announcement also identifies a separate billing practice in the physician’s own examinations. When he examined patients, he used procedure codes describing more complex and lengthier examinations than he performed. His role therefore reached both the tests he authorized and the services billed under his examination codes.

For a billing employee, those are distinct comparisons. The testing claim can be compared with the order, the medical-necessity certificate and the patient’s encounter history. The examination claim can be compared with the work the physician actually performed. Someone who saw both processes can explain how the same clinical signature supported different kinds of payment requests.

The earlier urine-testing article describes the broader incentive: a treatment center or physician could receive compensation tied to each referred test or to testing volume. That makes the decision to order another test financially valuable to the person directing referrals. In this criminal case, the Justice Department’s account identifies the operator’s laboratory payments as the reason for choosing the tests and their frequency.

We see the absurdity in the arrangement: the clinical decision appeared under a physician’s signature, but the laboratory’s payments helped determine the order. The signature gave a medical appearance to a decision made elsewhere. An insider who knows how the order reached the physician can explain the decision that the signed form leaves out.

In American Therapeutic Corporation’s separate criminal case, the Eleventh Circuit’s account of the trial evidence described a physician rapidly signing treatment plans and recertifications without making the required clinical determinations. That comparison makes the work behind a signature the issue: who reviewed the patient information, what decision followed and how the approval entered a bill.

The Order, the Review and the Insurance Claim

The clinical worker and the organization submitting the claim can be different. A treatment program manages staffing and records, a physician makes medical decisions, and a laboratory handles testing. Following the work across those boundaries shows where a clinical decision became a payment request.

For this testing scheme, the important connection runs from the reason for the order through the review of the result to the service billed. The urine-testing article describes how the number of substances tested and the codes billed affect the size of a claim. It also describes programs using standing testing protocols without physician involvement.

A program may use a urine test to verify sobriety or deter drug use, the article explains. Testing ordered and reviewed as part of medical treatment carries a further clinical purpose. That distinction gives a billing or laboratory insider something specific to recognize: whether the claim reflects a physician’s assessment or the program’s standing testing routine.

Clinical Signoff and a Whistleblower Case

When false testing claims reach Medicare, the clinical work behind the claim matters to a potential whistleblower case. The person who understands the difference between the documented approval and what actually happened can bring something the billing record alone leaves out.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. We work with treatment and laboratory insiders to assess the claims, the payer and the decisions that kept the testing going.

You Know What the Signoff Meant

If you saw test approvals moving faster than the clinical work behind them, speak with our whistleblower experts about what happened inside the program. We help build your case around the testing decisions and claims, bring in healthcare fraud whistleblower lawyers who understand treatment and laboratory billing, and stay beside you throughout the case.